A Study of Milvexian in Healthy Adult Females

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study is to measure the effect of milvexian given for approximately 2 weeks on (a) how the liver metabolizes other drugs (in this case one called midazolam), and (b) the pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of an oral contraceptive pill in healthy adult females.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05875571` - Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement	Phase 4
Suspended	`NCT03296098` - Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive	Phase 2
Not yet recruiting	`NCT06346457` - Breast Cancer & Antiestrogenic Therapy & Brain

NCT number	NCT05706753
Study type	Interventional
Source	Janssen Pharmaceutica N.V., Belgium
Contact
Status	Completed
Phase	Phase 1
Start date	January 25, 2023
Completion date	July 20, 2023

A Study of Milvexian in Healthy Adult Females

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms